サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1588718

吸入および点鼻スプレージェネリック医薬品市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、患者層別、最終用途別、流通チャネル別、地域別、セグメント予測、2025年-2030年

Inhalation And Nasal Spray Generic Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Patient Demographics, By End-use, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 160 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
吸入および点鼻スプレージェネリック医薬品市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、患者層別、最終用途別、流通チャネル別、地域別、セグメント予測、2025年-2030年
出版日: 2024年10月28日
発行: Grand View Research
ページ情報: 英文 160 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

吸入および点鼻スプレージェネリック医薬品市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の吸入および点鼻スプレージェネリック医薬品市場規模は2030年までに490億9,000万米ドルに達し、2025年から2030年までのCAGRは8.56％を記録すると予測されています。

新製品の上市、慢性呼吸器疾患の蔓延、費用対効果の高い医薬品への需要の高まり、高齢人口の増加などが市場成長を後押しする主な要因です。

費用対効果の高い医薬品に対する需要の高まりと、ジェネリック医薬品の使用に対する政府の支援は、予測期間中、吸入および点鼻スプレージェネリック医薬品の需要を促進すると予想されます。例えば、日本政府は全体的な医薬品支出を調整するため、安価なジェネリック医薬品の使用を推進してきました。これは、過去10年間にジェネリック医薬品の使用を奨励する規制を実施することで達成されました。

Teva Pharmaceuticals、Glenmark Specialty S.A.、Hikma Pharmaceuticals PLCを含む大手メーカー間のM&A、提携、協力関係の増加も成長を促進する主要因です。例えば、2022年1月、Glenmark Pharmaceuticals Ltd.のスイス子会社であるGlenmark Specialty S.A.は、Lotus International Pte.Ltd.と提携し、ベトナム、香港、シンガポールでリヤルトリス点鼻薬を販売します。この契約に基づき、グレンマーク・スペシャリティS.A.はリヤルトリスの製造と供給を行い、ロータス・インターナショナルPte.Ltd.が商業化します。同様に、2020年2月、グレンマーク・スペシャルティは米国でリャルトリシンを商業化するためのライセンス契約をヒクマ・ファーマシューティカルズPLCと締結しました。

製薬会社による呼吸器領域の創薬における広範な調査と吸入・経鼻薬のジェネリック製品承認が成長を促進すると予測されています。例えば、2021年3月、Cipla Inc.は片頭痛治療を適応とするImitrex Nasal Sprayのジェネリック医薬品であるSumatriptan Nasal SprayのANDA承認を米国FDAから取得しました。また、2020年5月には、Migranalの後発品であるDihydroergotamine Mesylate Nasal SprayのANDA承認とともに、FDAから競合後発品（Competitive Generic Therapy）の指定を受けた。

吸入および点鼻スプレージェネリック医薬品市場レポートハイライト

  • 薬剤クラス別では、気管支拡張薬セグメントが2024年に29.84%の最大売上シェアで市場をリード。世界市場における気管支拡張薬セグメントの成長は、喘息やその他の呼吸器疾患に対する即効性のある治療に対する需要の増加によって牽引されると予測されます。
  • 適応症別では、喘息分野が2024年に42.85％の最大収益シェアで市場をリードしました。
  • 患者層別では、成人患者セグメントが2024年に43.50％の最大売上シェアで市場をリードしました。
  • 最終用途別では、在宅介護セグメントが2024年に55.86％の最大売上シェアで市場をリードしました。
  • 流通チャネル別では、小売薬局セグメントが2024年に56.96％の最大収益シェアで市場をリードしました。
  • 北米の吸入および点鼻スプレージェネリック医薬品市場は、2024年に38.54％の売上シェアで市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 吸入および点鼻スプレージェネリック医薬品市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 吸入および点鼻スプレージェネリック医薬品市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 吸入および点鼻スプレージェネリック医薬品市場：薬剤クラスの推定・動向分析

  • セグメントダッシュボード
  • 世界の吸入および点鼻スプレージェネリック医薬品市場：薬剤クラスの変動分析
  • 薬剤クラス別、収益
  • 気管支拡張薬
  • 併用薬
  • コルチコステロイド
  • 充血除去スプレー
  • 抗ヒスタミン薬
  • その他

第5章 吸入および点鼻スプレージェネリック医薬品市場：適応症推定・動向分析

  • セグメントダッシュボード
  • 世界の吸入および点鼻スプレージェネリック医薬品市場：適応症変動分析
  • 適応症別、収益
  • 喘息
  • 慢性閉塞性肺疾患（COPD）
  • アレルギー性鼻炎
  • その他

第6章 吸入および点鼻スプレージェネリック医薬品市場：患者の人口統計推定・動向分析

  • セグメントダッシュボード
  • 世界の吸入および点鼻スプレージェネリック医薬品市場：患者人口変動分析
  • 患者層別、収益
  • 成人患者
  • 小児患者
  • 高齢患者

第7章 吸入および点鼻スプレージェネリック医薬品市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • 世界の吸入および点鼻スプレージェネリック医薬品市場：最終用途変動分析
  • 最終用途別、収益
  • 在宅ケア
  • 病院
  • その他

第8章 吸入および点鼻スプレージェネリック医薬品市場：流通チャネルの推定・動向分析

  • セグメントダッシュボード
  • 世界の吸入および点鼻スプレージェネリック医薬品市場：流通チャネル変動分析
  • 流通チャネル別、収益
  • 小売薬局
  • 病院薬局
  • オンライン薬局

第9章 吸入および点鼻スプレージェネリック医薬品市場：製品、用途、最終用途別の地域別推定・動向分析

  • 地域ダッシュボード
  • 市場規模と予測動向分析、2018年から2030年：
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • ノルウェー
    • スウェーデン
    • デンマーク
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第10章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • 主要企業の市場シェア分析、2024年
    • Teva Pharmaceuticals Industries Ltd
    • Viatris Inc.
    • Akorn Operating Company Llc.
    • Cipla
    • Sandoz Group Ag
    • Apotex Inc.
    • Hikma Pharmaceuticals Plc
    • Beximco Pharmaceuticals Ltd
    • Sun Pharmaceutical Industries Ltd
図表

List Of Tables

  • Table 1. List Of Abbreviation
  • Table 2. List Of Secondary Sources
  • Table 3. List Of Abbreviation
  • Table 4. North America Inhalation & Nasal Spray Generic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 5. North America Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 6. North America Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 7. North America Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 8. North America Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 9. North America Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 10. U.S. Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 11. U.S. Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 12. U.S. Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 13. U.S. Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 14. U.S. Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 15. Canada Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 16. Canada Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 17. Canada Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 18. Canada Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 19. Canada Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 20. Mexico Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 21. Mexico Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 22. Mexico Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 23. Mexico Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24. Mexico Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 25. Europe Inhalation & Nasal Spray Generic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 26. Europe Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 27. Europe Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 28. Europe Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 29. Europe Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30. Europe Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 31. Germany Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32. Germany Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 33. Germany Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 34. Germany Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 35. Germany Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 36. Uk Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 37. Uk Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 38. Uk Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 39. Uk Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 40. Uk Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 41. France Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 42. France Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 43. France Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 44. France Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 45. France Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 46. Italy Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 47. Italy Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 48. Italy Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 49. Italy Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 50. Italy Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 51. Spain Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 52. Spain Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 53. Spain Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 54. Spain Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 55. Spain Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 56. Denmark Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 57. Denmark Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 58. Denmark Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 59. Denmark Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 60. Denmark Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 61. Sweden Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 62. Sweden Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 63. Sweden Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 64. Sweden Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 65. Sweden Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 66. Norway Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67. Norway Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 68. Norway Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 69. Norway Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 70. Norway Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 71. Asia Pacific Inhalation & Nasal Spray Generic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 72. Asia Pacific Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73. Asia Pacific Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 74. Asia Pacific Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 75. Asia Pacific Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 76. Asia Pacific Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 77. Japan Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 78. Japan Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 79. Japan Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 80. Japan Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 81. Japan Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 82. China Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 83. China Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 84. China Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 85. China Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 86. China Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 87. India Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 88. India Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 89. India Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 90. India Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 91. India Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 92. South Korea Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 93. South Korea Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 94. South Korea Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 95. South Korea Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 96. South Korea Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 97. Australia Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 98. Australia Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 99. Australia Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 100. Australia Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 101. Australia Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 102. Thailand Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 103. Thailand Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 104. Thailand Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 105. Thailand Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 106. Thailand Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 107. Latin America Inhalation & Nasal Spray Generic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 108. Latin America Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 109. Latin America Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 110. Latin America Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 111. Latin America Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 112. Latin America Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 113. Brazil Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 114. Brazil Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 115. Brazil Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 116. Brazil Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 117. Brazil Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 118. Argentina Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 119. Argentina Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 120. Argentina Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 121. Argentina Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 122. Argentina Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 123. Middle East & Africa Inhalation & Nasal Spray Generic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 124. Middle East & Africa Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 125. Middle East & Africa Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 126. Middle East & Africa Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 127. Middle East & Africa Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 128. Middle East & Africa Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 129. Saudi Arabia Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 130. Saudi Arabia Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 131. Saudi Arabia Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 132. Saudi Arabia Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 133. Saudi Arabia Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 134. South Africa Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 135. South Africa Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 136. South Africa Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 137. South Africa Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 138. South Africa Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 139. Uae Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 140. Uae Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 141. Uae Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 142. Uae Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 143. Uae Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)
  • Table 144. Kuwait Inhalation & Nasal Spray Generic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 145. Kuwait Inhalation & Nasal Spray Generic Drugs Market, By Indication, 2018 - 2030 (USD Million)
  • Table 146. Kuwait Inhalation & Nasal Spray Generic Drugs Market, By Patient Demographics, 2018 - 2030 (USD Million)
  • Table 147. Kuwait Inhalation & Nasal Spray Generic Drugs Market, By End Use, 2018 - 2030 (USD Million)
  • Table 148. Kuwait Inhalation & Nasal Spray Generic Drugs Market, By Distribution Channel 2018 - 2030 (USD Million)

List Of Figures

  • Fig 1. Inhalation & Nasal Spray Generic Drugs Market Segmentation
  • Fig 2. Market Research Process
  • Fig 3. Data Triangulation Techniques
  • Fig 4. Primary Research Pattern
  • Fig 5. Market Research Approaches
  • Fig 6. Value-Chain-Based Sizing & Forecasting
  • Fig 7. Qfd Modeling For Market Share Assessment
  • Fig 8. Market Formulation & Validation
  • Fig 9. Inhalation & Nasal Spray Generic Drugs Market Snapshot
  • Fig 10. Parent Market Outlook
  • Fig 11. Related/Ancillary Market Outlook, Revenue, 2024 (USD Million)
  • Fig 12. Penetration And Growth Prospect Mapping
  • Fig 13. Inhalation & Nasal Spray Generic Drugs Market Driver Impact
  • Fig 14. Inhalation & Nasal Spray Generic Drugs Market Restraint Impact
  • Fig 15. Swot Analysis, By Factor (Political & Legal, Economic, And Technological)
  • Fig 16. Industry Analysis - Porter's
  • Fig 17. Strategy Mapping
  • Fig 18. Inhalation & Nasal Spray Generic Drugs Market: Drug Class Outlook And Key Takeaways
  • Fig 19. Inhalation & Nasal Spray Generic Drugs Market: Drug Class Movement Analysis & Market
  • Fig 20. Bronchodilators Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 21. Combination Drugs Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 22. Corticosteroids Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 23. Decongestant Sprays Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 24. Antihistamines Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 25. Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 26. Inhalation & Nasal Spray Generic Drugs Market: Indication Outlook And Key Takeaways
  • Fig 27. Inhalation & Nasal Spray Generic Drugs Market: Indication Movement Analysis & Market
  • Fig 28. Asthma Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 29. Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 30. Allergic Rhinitis Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 31. Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 32. Inhalation & Nasal Spray Generic Drugs Market: Patient Demographics Outlook And Key
  • Fig 33. Inhalation & Nasal Spray Generic Drugs Market: Patient Demographics Movement Analysis
  • Fig 34. Adult Patient Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 35. Pediatric Patient Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 36. Geriatric Patient Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 37. Inhalation & Nasal Spray Generic Drugs Market: End-Use Outlook And Key Takeaways
  • Fig 38. Inhalation & Nasal Spray Generic Drugs Market: End-Use Movement Analysis & Market
  • Fig 39. Homecare Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 40. Hospitals Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 41. Others Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 42. Inhalation & Nasal Spray Generic Drugs Market: Distribution Channel Outlook And Key
  • Fig 43. Inhalation & Nasal Spray Generic Drugs Market: Distribution Channel Movement Analysis
  • Fig 44. Retail Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 45. Hospitals Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 46. Online Pharmacies Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • Fig 47. Global Inhalation And Nasal Spray Generic Drugs Market: Regional Movement Analysis
  • Fig 48. Global Inhalation And Nasal Spray Generic Drugs Market: Regional Outlook And Key Takeaways
  • Fig 49. Global Inhalation And Nasal Spray Generic Drugs Market Share And Leading Players
  • Fig 50. North America, By Country
  • Fig 51. North America Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 52. U.S. Key Country Dynamics
  • Fig 53. U.S. Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 54. Canada Key Country Dynamics
  • Fig 55. Canada Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 56. Mexico Key Country Dynamics
  • Fig 57. Mexico Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 58. Europe Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 59. Uk Key Country Dynamics
  • Fig 60. Uk Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 61. Germany Key Country Dynamics
  • Fig 62. Germany Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 63. France Key Country Dynamics
  • Fig 64. France Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 65. Italy Key Country Dynamics
  • Fig 66. Italy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 67. Spain Key Country Dynamics
  • Fig 68. Spain Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 69. Denmark Key Country Dynamics
  • Fig 70. Denmark Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 71. Sweden Key Country Dynamics
  • Fig 72. Sweden Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 73. Norway Key Country Dynamics
  • Fig 74. Norway Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 75. Asia Pacific Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 76. China Key Country Dynamics
  • Fig 77. China Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 78. Japan Key Country Dynamics
  • Fig 79. Japan Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 80. India Key Country Dynamics
  • Fig 81. India Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 82. Thailand Key Country Dynamics
  • Fig 83. Thailand Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 84. South Korea Key Country Dynamics
  • Fig 85. South Korea Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 86. Australia Key Country Dynamics
  • Fig 87. Australia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 88. Latin America Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 89. Brazil Key Country Dynamics
  • Fig 90. Brazil Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 91. Argentina Key Country Dynamics
  • Fig 92. Argentina Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 93. Middle East And Africa Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 94. South Africa Key Country Dynamics
  • Fig 95. South Africa Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 96. Saudi Arabia Key Country Dynamics
  • Fig 97. Saudi Arabia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 98. UAE Key Country Dynamics
  • Fig 99. UAE Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 100. Kuwait Key Country Dynamics
  • Fig 101. Kuwait Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • Fig 102. Market Share Analysis Of Key Market Players, 2024
目次
Product Code: GVR-4-68039-965-9

Inhalation And Nasal Spray Generic Drugs Market Growth & Trends:

The global inhalation and nasal spray generic drugs market size is expected to reach USD 49.09 billion by 2030, registering a CAGR of 8.56% from 2025 to 2030, according to a new report by Grand View Research, Inc. New product launches, mounting prevalence of chronic respiratory diseases, growing demand for cost-effective medicines, and rising geriatric population are some of the major factors boosting the market growth.

Rising demand for cost-effective medicines and government support for the use of generics is expected to drive the demand for inhalation and nasal spray generic drugs over the forecast period. For instance, the Government of Japan has been promoting the usage of inexpensive generic drugs in order to regulate the overall pharmaceutical expenditure. This was accomplished through the execution of regulations to encourage the use of generic drugs in the past decade.

Rising number of M&A, partnerships, and collaborations among leading manufacturers including Teva Pharmaceuticals, Glenmark Specialty S.A., and Hikma Pharmaceuticals PLC is another major factor propelling the growth. For instance, in January 2022, Glenmark Specialty S.A., a Swiss subsidiary of Glenmark Pharmaceuticals Ltd., partnered with Lotus International Pte. Ltd. for marketing Ryaltris nasal spray in Vietnam, Hong Kong, and Singapore. Under this agreement, Glenmark Specialty S.A. will manufacture and supply Ryaltris, and Lotus International Pte. Ltd. will commercialize the product. Similarly, in February 2020, Glenmark Specialty signed a licensing agreement with Hikma Pharmaceuticals PLC to commercialize Ryaltrisin in the U.S.

Extensive research in the respiratory drug discovery and generic product approvals of inhalation and nasal drugs by pharmaceutical companies are projected to fuel growth. For instance, in March 2021, Cipla Inc. received ANDA approval from the U.S. FDA for Sumatriptan Nasal Spray, a generic equivalent of Imitrex Nasal Spray indicated for migraine treatment. In addition, in May 2020, the company received Competitive Generic Therapy designation from FDA along with ANDA approval for Dihydroergotamine Mesylate Nasal Spray, a generic version of Migranal.

Inhalation And Nasal Spray Generic Drugs Market Report Highlights:

  • By drug class, the bronchodilators segment led the market with the largest revenue share of 29.84% in 2024. The growth of the bronchodilator drug segment in the global market is expected to be driven by the increasing demand for quick-relief treatments for asthma and other respiratory conditions
  • Based on indication, the asthma segment led the market with the largest revenue share of 42.85% in 2024.
  • Based on patient demographics, the adult patient segment led the market with the largest revenue share of 43.50% in 2024.
  • Based on end-use, the homecare segment led the market with the largest revenue share of 55.86% in 2024.
  • Based on distribution channel, the retail pharmacies segment led the market with the largest revenue share of 56.96% in 2024.
  • North America inhalation and nasal spray generic drugs market dominated the inhalation and nasal spray generic drugs market with the revenue share of 38.54% in 2024.

Table Of Contents

Chapter 1. Methodology And Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Patient Demographics
    • 1.2.4. End Use
    • 1.2.5. Distribution Channel
    • 1.2.6. Regional Scope
    • 1.2.7. Estimates And Forecasts Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. Gvr's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details Of Primary Research
      • 1.4.5.1. Data For Primary Interviews In North America
      • 1.4.5.2. Data For Primary Interviews In Europe
      • 1.4.5.3. Data For Primary Interviews In Asia Pacific
      • 1.4.5.4. Data For Primary Interviews In Latin America
      • 1.4.5.5. Data For Primary Interviews In Mea
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis (Model 1)
    • 1.7.2. Approach 1: Commodity Flow Approach
    • 1.7.3. Volume Price Analysis (Model 2)
    • 1.7.4. Approach 2: Volume Price Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class And Indication Outlook
    • 2.2.2. Patient Demographics And End Use
    • 2.2.3. Distribution Channel Outlook
  • 2.3. Competitive Insights

Chapter 3. Inhalation And Nasal Spray Generic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence Of Respiratory Disease
      • 3.2.1.2. Rising Awareness About Disease
      • 3.2.1.3. Technological Advancement In Drug Development And Delivery
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Low Adoption Of Treatment In Low Middle Income Countries
      • 3.2.2.2. High Competition And Low Profit Margin
  • 3.3. Inhalation And Nasal Spray Generic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat Of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. Pestel Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape

Chapter 4. Inhalation And Nasal Spray Generic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Inhalation And Nasal Spray Generic Drugs Market: Drug Class Movement Analysis
  • 4.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Drug Class, Revenue (USD Million)
  • 4.4. Bronchodilators
    • 4.4.1. Bronchodilators Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.5. Combination Drugs
    • 4.5.1. Combination Drugs Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.6. Corticosteroids
    • 4.6.1. Corticosteroids Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.7. Decongestant Sprays
    • 4.7.1. Decongestant Sprays Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.8. Antihistamines
    • 4.8.1. Antihistamines Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 5. Inhalation And Nasal Spray Generic Drugs Market: Indication Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Inhalation And Nasal Spray Generic Drugs Market: Indication Movement Analysis
  • 5.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Indication, Revenue (USD Million)
  • 5.4. Asthma
    • 5.4.1. Asthma Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.5. Chronic Obstructive Pulmonary Disease (Copd)
    • 5.5.1. Chronic Obstructive Pulmonary Disease (Copd) Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.6. Allergic Rhinitis
    • 5.6.1. Allergic Rhinitis Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 6. Inhalation And Nasal Spray Generic Drugs Market: Patient Demographics Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Inhalation And Nasal Spray Generic Drugs Market: Patient Demographics Movement Analysis
  • 6.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Patient Demographics, Revenue (USD Million)
  • 6.4. Adult Patient
    • 6.4.1. Adult Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.5. Pediatric Patient
    • 6.5.1. Pediatric Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 6.6. Geriatric Patient
    • 6.6.1. Geriatric Patient Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 7. Inhalation And Nasal Spray Generic Drugs Market: End Use Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Global Inhalation And Nasal Spray Generic Drugs Market: End Use Movement Analysis
  • 7.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By End Use, Revenue (USD Million)
  • 7.4. Homecare
    • 7.4.1. Homecare Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 7.5. Hospitals
    • 7.5.1. Hospitals Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 7.6. Others
    • 7.6.1. Others Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 8. Inhalation And Nasal Spray Generic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Global Inhalation And Nasal Spray Generic Drugs Market: Distribution Channel Movement Analysis
  • 8.3. Global Inhalation And Nasal Spray Generic Drugs Market Estimates And Forecasts, By Distribution Channel, Revenue (USD Million)
  • 8.4. Retail Pharmacies
    • 8.4.1. Retail Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 8.5. Hospitals Pharmacies
    • 8.5.1. Hospitals Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 8.6. Online Pharmacies
    • 8.6.1. Online Pharmacies Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 9. Inhalation And Nasal Spray Generic Drugs Market: Regional Estimates & Trend Analysis By Product, Application, And End Use

  • 9.1. Regional Dashboard
  • 9.2. Market Size & Forecasts Trend Analysis, 2018 To 2030:
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key Country Dynamics
      • 9.3.1.2. Regulatory Framework/ Reimbursement Structure
      • 9.3.1.3. Competitive Scenario
      • 9.3.1.4. U.S. Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key Country Dynamics
      • 9.3.2.2. Regulatory Framework/ Reimbursement Structure
      • 9.3.2.3. Competitive Scenario
      • 9.3.2.4. Canada Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key Country Dynamics
      • 9.3.3.2. Regulatory Framework/ Reimbursement Structure
      • 9.3.3.3. Competitive Scenario
      • 9.3.3.4. Mexico Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. Uk
      • 9.4.1.1. Key Country Dynamics
      • 9.4.1.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.1.3. Competitive Scenario
      • 9.4.1.4. Uk Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.2.3. Competitive Scenario
      • 9.4.2.4. Germany Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.3.3. Competitive Scenario
      • 9.4.3.4. France Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.4.3. Competitive Scenario
      • 9.4.4.4. Italy Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key Country Dynamics
      • 9.4.5.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.5.3. Competitive Scenario
      • 9.4.5.4. Spain Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.6. Norway
      • 9.4.6.1. Key Country Dynamics
      • 9.4.6.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.6.3. Competitive Scenario
      • 9.4.6.4. Norway Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.7. Sweden
      • 9.4.7.1. Key Country Dynamics
      • 9.4.7.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.7.3. Competitive Scenario
      • 9.4.7.4. Sweden Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.4.8. Denmark
      • 9.4.8.1. Key Country Dynamics
      • 9.4.8.2. Regulatory Framework/ Reimbursement Structure
      • 9.4.8.3. Competitive Scenario
      • 9.4.8.4. Denmark Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key Country Dynamics
      • 9.5.1.2. Regulatory Framework/ Reimbursement Structure
      • 9.5.1.3. Competitive Scenario
      • 9.5.1.4. Japan Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Regulatory Framework/ Reimbursement Structure
      • 9.5.2.3. Competitive Scenario
      • 9.5.2.4. China Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Regulatory Framework/ Reimbursement Structure
      • 9.5.3.3. Competitive Scenario
      • 9.5.3.4. India Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Regulatory Framework/ Reimbursement Structure
      • 9.5.4.3. Competitive Scenario
      • 9.5.4.4. Australia Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Regulatory Framework/ Reimbursement Structure
      • 9.5.5.3. Competitive Scenario
      • 9.5.5.4. South Korea Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Regulatory Framework/ Reimbursement Structure
      • 9.5.6.3. Competitive Scenario
      • 9.5.6.4. Thailand Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key Country Dynamics
      • 9.6.1.2. Regulatory Framework/ Reimbursement Structure
      • 9.6.1.3. Competitive Scenario
      • 9.6.1.4. Brazil Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Regulatory Framework/ Reimbursement Structure
      • 9.6.2.3. Competitive Scenario
      • 9.6.2.4. Argentina Market Estimates And Forecasts 2018 To 2030 (USD Million)
  • 9.7. Mea
    • 9.7.1. South Africa
      • 9.7.1.1. Key Country Dynamics
      • 9.7.1.2. Regulatory Framework/ Reimbursement Structure
      • 9.7.1.3. Competitive Scenario
      • 9.7.1.4. South Africa Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Regulatory Framework/ Reimbursement Structure
      • 9.7.2.3. Competitive Scenario
      • 9.7.2.4. Saudi Arabia Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.7.3. Uae
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Regulatory Framework/ Reimbursement Structure
      • 9.7.3.3. Competitive Scenario
      • 9.7.3.4. Uae Market Estimates And Forecasts 2018 To 2030 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Regulatory Framework/ Reimbursement Structure
      • 9.7.4.3. Competitive Scenario
      • 9.7.4.4. Kuwait Market Estimates And Forecasts 2018 To 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. Key Company Market Share Analysis, 2024
    • 10.3.2. Teva Pharmaceuticals Industries Ltd
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Product Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Viatris Inc.
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Product Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. Akorn Operating Company Llc.
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Product Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Cipla
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Product Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Sandoz Group Ag
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Product Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. Apotex Inc.
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Product Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Hikma Pharmaceuticals Plc
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Product Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Beximco Pharmaceuticals Ltd
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Product Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Sun Pharmaceutical Industries Ltd
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Product Benchmarking
      • 10.3.10.4. Strategic Initiatives